News und Analysen
Silence Therapeutics Completes Enrollment in Phase 2 Study of Zerlasiran (SLN360) in Subjects with Elevated Lipoprotein(a) at High Risk of Atherosclerotic Cardiovascular Disease Events
Silence Therapeutics plc, Nasdaq: SLN (“Silence” or “the Company”), an experienced and innovative biotechnology company committed to transforming people’s lives by silencing diseases through
Silence Therapeutics to Participate in Fireside Chat at H.C. Wainwright BioConnect Investor Conference
Silence Therapeutics plc, Nasdaq: SLN (“Silence” or “the Company”), an experienced and innovative biotechnology company committed to transforming people’s lives by silencing diseases through
Form 8.3 - The Vanguard Group, Inc.: Dechra Pharmaceuticals PLC
Form 8.3 - The Vanguard Group, Inc.: Dechra Pharmaceuticals plc
Form 8.3 - The Vanguard Group, Inc.: Dechra Pharmaceuticals plc
Form 8.3 - The Vanguard Group, Inc.: Dechra Pharmaceuticals plc
Form 8.3 - The Vanguard Group, Inc.: Dechra Pharmaceuticals plc
Form 8.3 - The Vanguard Group, Inc.: Dechra Pharmaceuticals plc
Form 8.3 - The Vanguard Group, Inc.: Dechra Pharmaceuticals plc
Form 8.3 - The Vanguard Group, Inc.: Dechra Pharmaceuticals plc
Convatec Group PLC: Scrip Dividend - Calculation Price
Form 8.3 - The Vanguard Group, Inc.: Dechra Pharmaceuticals plc
Hardman & Co Research on Tissue Regenix (TRX): Turning profitable and cash-generative
LivaNova to Announce First-Quarter 2023 Results
LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology and innovation company, will host a conference call to discuss its first-quarter 2023 results on Wednesday, May 3, 2023 at 1 p.m
Convatec Group PLC: Annual Report and Accounts 2022 and Notice of AGM
Silence Therapeutics Reports Fourth Quarter and Full Year 2022 Results
Silence Therapeutics plc, Nasdaq: SLN (“Silence” or “the Company”), an experienced and innovative biotechnology company committed to transforming people’s lives by silencing diseases through
LivaNova to Present at the Barclays Global Healthcare Conference
LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology and innovation company, today announced Damien McDonald, Chief Executive Officer, will present in a fireside chat at the Barclays
Silence Therapeutics to Report Fourth Quarter and Full Year 2022 Results on March 15, 2023
Silence Therapeutics plc, Nasdaq: SLN (“Silence” or “the Company”), an experienced and innovative biotechnology company committed to transforming people’s lives by silencing diseases through
LivaNova Reports Fourth-Quarter and Full-Year 2022 Results
LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology and innovation company, today reported results for the quarter and full year ended December 31, 2022 and issued guidance for 2023.
Silence Therapeutics to Present at SVB Securities Global Biopharma Conference
Silence Therapeutics plc, Nasdaq: SLN (“Silence” or “the Company”), an experienced and innovative biotechnology company committed to transforming people’s lives by silencing diseases through
LivaNova to Announce Fourth-Quarter and Full-Year 2022 Results
LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology and innovation company, will host a conference call to discuss its fourth-quarter and full-year 2022 results on Wednesday, February